Pancreatic cancer is a highly aggressive malignancy with poor prognosis and high mortality rates.
KRAS mutations are ubiquitous in pancreatic cancer and drive tumorigenesis by promoting uncontrolled cell proliferation, survival, and metastasis.
Therefore, identifying therapeutic agents effective against KRAS-mutant pancreatic cancer are urgent.
Erianin, a benzyl compound isolated from Dendrobium candidum, exhibited potent cytotoxicity in KRAS-mutant pancreatic cancer cells (PANC-1: IC
